Key Highlights
- Third-quarter 2026 net loss was USD 51.3 million, or USD 0.15 per share.
- Research and development expenses were USD 47.2 million, against USD 22.5 million.
- Cash and equivalents were USD 119.0 million; short-term marketable securities were USD 524.7 million.
- The company completed a January 2026 offering of 25,875,000 shares at USD 10.00.
Erasca (NASDAQ:ERAS) reported a third-quarter 2026 net loss of USD 51.3 million, or USD 0.15 per share, against an estimate of a loss of USD 0.13 per share, in its Quarterly Report on Form 10-Q. The clinical-stage oncology company reported no Revenue for the quarter. Its filing describes a RAS-targeting Franchise that includes ERAS-0015, a pan-RAS molecular glue, and ERAS-4001.
Quarterly Results
Research and development expenses were USD 47.2 million for the three months ended September 30, 2026, against USD 22.5 million a year earlier. The filing states the USD 24.7 million increase was primarily driven by USD 15.3 million in clinical trial, preclinical study and discovery expenses, USD 5.8 million in personnel costs including stock-based compensation, and USD 3.7 million in outsourced services and consulting fees.
In-process Research and Development expenses were zero, against USD 2.0 million a year earlier, which related to milestones under the Medshine license agreement. General and administrative expenses were USD 12.3 million, against USD 10.1 million, and the filing attributes the USD 2.3 million increase to personnel costs.
Total operating expenses were USD 59.5 million, against USD 34.5 million, and the loss from operations was USD 59.5 million. Other income, net, was USD 8.2 million, against USD 3.9 million, primarily reflecting higher interest earned on cash, cash equivalents and marketable securities. Net loss was USD 51.3 million, against USD 30.6 million.
For the nine months, net loss was USD 278.9 million, or USD 0.87 per share, against USD 95.5 million, or USD 0.34 per share. Total operating expenses for the nine months were USD 295.1 million, against USD 108.3 million.
Pipeline Developments
The filing describes ERAS-0015 as a pan-RAS molecular glue in clinical development for patients with RAS-mutated solid tumors. The company states that, in vitro, it has shown approximately 8-21 times higher binding affinity to cyclophilin A than the most advanced pan-RAS molecular glue in development. The corporate milestones listed include reporting data from the ongoing Phase 1 trial of ERAS-0015 and initiating potentially registration-enabling trials in second-line and later non-small cell lung cancer, first-line pancreatic ductal adenocarcinoma and RAS-mutated non-small cell lung cancer.
The company also lists reporting monotherapy data from the ongoing Phase 1 trial of ERAS-4001 and initiating monotherapy expansion cohorts and combination dose escalation cohorts. It states that ERAS-4001 could also address more than 2.2 million patients with KRAS-mutant tumors.
The filing states the company decided to stop development of naporafenib. In March 2026, it sent a notice to Novartis to terminate the related agreement, with an effective termination date of June 3, 2026.
Balance Sheet and Financing
At September 30, 2026, cash and cash equivalents were USD 119.0 million, short-term marketable securities were USD 524.7 million and long-term marketable securities were USD 304.1 million, against USD 73.8 million, USD 202.3 million and USD 65.7 million at December 31, 2025. Total Assets were USD 998.9 million, against USD 396.2 million, and total stockholders' Equity was USD 916.7 million.
In January 2026, the company completed the sale and issuance of 25,875,000 shares of common stock, including the full exercise of the underwriters' option to purchase 3,375,000 shares, at a public offering price of USD 10.00 per share. There were 350,239,401 shares of common stock outstanding at September 30, 2026, against 284,159,076 at December 31, 2025.
The company states it believes its cash, cash equivalents and marketable securities as of September 30, 2026 are sufficient to fund operations for at least one year from the issuance date of the financial statements, and to achieve the corporate milestones set out in the report. Accrued research and development expenses were USD 23.3 million, against USD 10.0 million.






Please wait processing your request...